Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bionxt Solutions Inc. (BNXT.CN)

Bionxt Solutions Inc. (BNXT.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 74,716
  • Shares Outstanding, K 122,486
  • Annual Sales, $ 27 K
  • Annual Income, $ -5,312 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 2.30
  • Price/Sales 4,399.75
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings $-0.01 on 11/28/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING:

    TSX Drug Specialty & Generic

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5300 +13.21%
on 02/04/26
0.6900 -13.04%
on 02/18/26
+0.0400 (+7.14%)
since 02/03/26
3-Month
0.4300 +39.53%
on 01/21/26
0.7500 -20.00%
on 12/11/25
-0.0600 (-9.09%)
since 12/03/25
52-Week
0.3800 +57.89%
on 04/07/25
1.1000 -45.45%
on 08/07/25
-0.0100 (-1.64%)
since 03/03/25

Most Recent Stories

More News
BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies

VANCOUVER, BC / November 4, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma...

BNXT.CN : 0.6000 (-1.64%)
BNXTF : 0.4553 (-5.13%)
BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization

VANCOUVER, BC / October 30, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

BNXT.CN : 0.6000 (-1.64%)
BNXTF : 0.4553 (-5.13%)
BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug

BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead product...

BNXT.CN : 0.6000 (-1.64%)
BNXTF : 0.4553 (-5.13%)
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study

VANCOUVER, BC / October 21, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies,...

BNXT.CN : 0.6000 (-1.64%)
BNXTF : 0.4553 (-5.13%)
BioNxt Solutions Announces Delay In Filing 2024 Annual Financial Statements

VANCOUVER, BC / ACCESS Newswire / May 1, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), announces that its annual financial statements for the year ended December...

BNXT.CN : 0.6000 (-1.64%)
BNXTF : 0.4553 (-5.13%)
BioNxt Solutions Prepares for Human Bioequivalence Study For MS

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems,...

BNXT.CN : 0.6000 (-1.64%)
BNXTF : 0.4553 (-5.13%)
BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

BNXT.CN : 0.6000 (-1.64%)
BNXTF : 0.4553 (-5.13%)
BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

BNXT.CN : 0.6000 (-1.64%)
BNXTF : 0.4553 (-5.13%)
BioNxt Solutions Announces Debenture Unit Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

BNXT.CN : 0.6000 (-1.64%)
BNXTF : 0.4553 (-5.13%)
Clarification of Promotional Activities

VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:4XT) reports a clarification to its news release dated January 31,...

BNXT.CN : 0.6000 (-1.64%)
BNXTF : 0.4553 (-5.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

BioNxt Solutions Inc is a cannabis company focused on next-generation drug formulations and delivery systems. Its pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, BNT24004. Its geographic areas are Austria, Germany, Switzerland, and Korea.

See More

Key Turning Points

3rd Resistance Point 0.6167
2nd Resistance Point 0.6133
1st Resistance Point 0.6067
Last Price 0.6000
1st Support Level 0.5967
2nd Support Level 0.5933
3rd Support Level 0.5867

See More

52-Week High 1.1000
Fibonacci 61.8% 0.8250
Fibonacci 50% 0.7400
Fibonacci 38.2% 0.6550
Last Price 0.6000
52-Week Low 0.3800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar